Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$113.87 USD

113.87
29,519,707

-1.57 (-1.36%)

Updated Jun 18, 2026 04:02 PM ET

After-Market: $114.10 +0.23 (0.20%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (96 out of 247)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Merck (MRK) Rises Higher Than Market: Key Facts

by Zacks Equity Research

In the latest trading session, Merck (MRK) closed at $100.69, marking a +1.52% move from the previous day.

Kinjel Shah headshot

3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment

by Kinjel Shah

J&J, ImmunityBio and Foghorn Therapeutics stand out as oncology players amid rapid innovation in cancer care with advancing pipelines, approvals and partnerships.

Kinjel Shah headshot

Eli Lilly or Merck: Where Should Investors Put Their Money?

by Kinjel Shah

LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer valuation.

Zacks Equity Research

MRK Gets Positive CHMP Opinion for Expanded Use of Winrevair in PAH

by Zacks Equity Research

Merck secures a positive CHMP opinion to expand Winrevair's PAH use, potentially broadening treatment to adult patients across WHO FC II-IV.

Ekta Bagri headshot

BMY Gains 13.1% in Three Months: Buy, Sell or Hold the Stock?

by Ekta Bagri

BMY shares are rebounding after a strong Q3, lifted by rising demand for Opdivo, Reblozyl and Camzyos, even as legacy drugs face generic pressure.

Zacks Equity Research

Can Opdivo's Label Expansions Help Bristol Myers Sustain Its Momentum?

by Zacks Equity Research

BMY gets a priority FDA review for Opdivo's use in previously untreated advanced Hodgkin lymphoma, reinforcing its oncology momentum.

Kanishka Das headshot

Can MRK's New Drugs & Pipeline Help Navigate the Looming Keytruda LOE?

by Kanishka Das

Merck leans on a fast-growing pipeline and new product launches to aid long-term growth as Keytruda's 2028 LOE nears.

Zacks Equity Research

Merck (MRK) Laps the Stock Market: Here's Why

by Zacks Equity Research

Merck (MRK) closed at $99.01 in the latest trading session, marking a +1.42% move from the prior day.

Sundeep Ganoria headshot

Here's How AbbVie's Oncology Drugs are Aiding Top-line Growth

by Sundeep Ganoria

ABBV's expanding oncology lineup, spanning new solid tumor drugs and rising Venclexta sales, is helping drive steady top-line growth.

Aparajita Dutta headshot

Pharma ETFs to Gain From Landmark UK-US Zero-Tariff Deal

by Aparajita Dutta

Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook.